Hyperinsulinemia Promotes Esophageal Cancer Development in a Surgically-Induced Duodeno-Esophageal Reflux Murine Model
Diletta Arcidiacono, Arben Dedja, Cinzia Giacometti, Matteo Fassan, Daniele Nucci, Simona Francia, Federico Fabris, Alice Zaramella, Emily J Gallagher, Mauro Cassaro, Massimo Rugge, Derek LeRoith, Alfredo Alberti, Stefano Realdon, Diletta Arcidiacono, Arben Dedja, Cinzia Giacometti, Matteo Fassan, Daniele Nucci, Simona Francia, Federico Fabris, Alice Zaramella, Emily J Gallagher, Mauro Cassaro, Massimo Rugge, Derek LeRoith, Alfredo Alberti, Stefano Realdon
Abstract
Hyperinsulinemia could have a role in the growing incidence of esophageal adenocarcinoma (EAC) and its pre-cancerous lesion, Barrett's Esophagus, a possible consequence of Gastro-Esophageal Reflux Disease. Obesity is known to mediate esophageal carcinogenesis through different mechanisms including insulin-resistance leading to hyperinsulinemia, which may mediate cancer progression via the insulin/insulin-like growth factor axis. We used the hyperinsulinemic non-obese FVB/N (Friend leukemia virus B strain) MKR (muscle (M)-IGF1R-lysine (K)-arginine (R) mouse model to evaluate the exclusive role of hyperinsulinemia in the pathogenesis of EAC related to duodeno-esophageal reflux. FVB/N wild-type (WT) and MKR mice underwent jejunum-esophageal anastomosis side-to end with the exclusion of the stomach. Thirty weeks after surgery, the esophagus was processed for histological, immunological and insulin/Insulin-like growth factor 1 (IGF1) signal transduction analyses. Most of the WT mice (63.1%) developed dysplasia, whereas most of the MKR mice (74.3%) developed squamous cell and adenosquamous carcinomas, both expressing Human Epidermal growth factor receptor 2 (HER2). Hyperinsulinemia significantly increased esophageal cancer incidence in the presence of duodenal-reflux. Insulin receptor (IR) and IGF1 receptor (IGF1R) were overexpressed in the hyperinsulinemic condition. IGF1R, through ERK1/2 mitogenic pattern activation, seems to be involved in cancer onset. Hyperinsulinemia-induced IGF1R and HER2 up-regulation could also increase the possibility of forming of IGF1R/HER2 heterodimers to support cell growth/proliferation/progression in esophageal carcinogenesis.
Keywords: MKR mouse model; duodenal reflux; esophageal cancer; human epidermal growth factor receptor 2; hyperinsulinemia; insulin-like growth factor 1 receptor.
Conflict of interest statement
The Authors declare no conflict of interest.
Figures
References
- Edgren G., Adami H.O., Weiderpass E., Nyrén O. A global assessment of the oesophageal adenocarcinoma epidemic. Gut. 2013;62:1406–1414. doi: 10.1136/gutjnl-2012-302412.
- Hvid-Jensen F., Pedersen L., Drewes A.M., Sørensen H.T., Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N. Engl. J. Med. 2011;365:1375–1383. doi: 10.1056/NEJMoa1103042.
- Miyashita T., Ohta T., Fujimura T., Ninomiya I., Fushida S., Hattori T., Miwa K. Duodenal juice stimulates oesophageal stem cells to induce Barrett’s oesophagus and oesophageal adenocarcinoma in rats. Oncol. Rep. 2006;15:1469–1475. doi: 10.3892/or.15.6.1469.
- Singh S., Sharma A.N., Murad M.H., Buttar N.S., El-Serag H.B., Katzka D.A., Iyer P.G. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: A systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2013;11:1399–1412. doi: 10.1016/j.cgh.2013.05.009.
- Manna P., Jain S.K. Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies. Metab. Syndr. Relat. Disord. 2015;13:423–444. doi: 10.1089/met.2015.0095.
- Fierz Y., Novosyadlyy R., Vijayakumar A., Yakar S., LeRoith D. Insulin-Sensitizing Therapy Attenuates Type 2 Diabetes–Mediated Mammary Tumor Progression. Diabetes. 2010;59:686–693. doi: 10.2337/db09-1291.
- Teng J.A., Wu S.G., Chen J.X., Li Q., Peng F., Zhu Z., Qin J., He Z.Y. The Activation of ERK1/2 and JNK MAPK Signaling by Insulin/IGF-1 Is Responsible for the Development of Colon Cancer with Type 2 Diabetes Mellitus. PLoS ONE. 2016;11:e0149822. doi: 10.1371/journal.pone.0149822.
- Novosyadlyy R., Lann D.E., Vijayakumar A., Rowzee A., Lazzarino D.A., Fierz Y., Carboni J.M., Gottardis M.M., Pennisi P.A., Molinolo A.A., et al. Insulin-mediated acceleration of breast cancer development and progression in a non-obese model of type 2 diabetes. Cancer Res. 2010;70:741–751. doi: 10.1158/0008-5472.CAN-09-2141.
- Ning Z., Yuanyuan Z., Hang Y.G., Jian H., Xiaodong C. Metformin and lung cancer risk of patients with type 2 diabetes mellitus: A meta-analysis. Biomed. Rep. 2015;3:235–241. doi: 10.3892/br.2015.417.
- Di Sebastiano K.M., Pinthus J.H., Duivenvoorden W.C.M., Mourtzakis M. Glucose impairments and insulin resistance in prostate cancer: The role of obesity, nutrition and exercise. Obes. Rev. 2018 doi: 10.1111/obr.12674.
- Jin Q., Esteva F.J. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J. Mammary Gland Biol. Neoplasia. 2008;13:485–498. doi: 10.1007/s10911-008-9107-3.
- Christopoulos P.F., Corthay A., Koutsilieris M. Aiming for the Insulin-like Growth Factor-1 system in breast cancer therapeutics. Cancer Treat. Rev. 2018;63:79–95. doi: 10.1016/j.ctrv.2017.11.010.
- Denduluri S.K., Idowu O., Wang Z., Liao Z., Yan Z., Mohammed M.K., Ye J., Wei Q., Wang J., Zhao L., et al. Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis. 2015;2:13–25. doi: 10.1016/j.gendis.2014.10.004.
- Bhattacharjee A., Allister E.M., Wheeler M.B. MK-626, a dipeptidyl peptidase-4 inhibitor, does not improve the hyperglycemia or hyperinsulinemia of nonobese diabetic MKR mice. Can. J. Physiol. Pharmacol. 2012;90:663–668. doi: 10.1139/y2012-039.
- LeRoith D., Werner H., Beitner-Johnson D., Roberts C.T., Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev. 1995;16:143–163. doi: 10.1210/edrv-16-2-143.
- Zick Y. Ser/Thr phosphorylation of IRS proteins: A molecular basis for insulin resistance. Sci. STKE. 2005;2005:pe4. doi: 10.1126/stke.2682005pe4.
- Zick Y. Insulin resistance: A phosphorylation-based uncoupling of insulin signaling. Trends Cell Biol. 2001;11:437–441. doi: 10.1016/S0962-8924(01)02129-8.
- Arcidiacono D., Antonello A., Fassan M., Nucci D., Morbin T., Agostini M., Nitti D., Rugge M., Alberti A., Battaglia G., et al. Insulin promotes HER2 signaling activation during Barrett’s Esophagus carcinogenesis. Dig. Liver Dis. 2017;49:630–638. doi: 10.1016/j.dld.2017.01.154.
- Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., Wolter J.M., Paton V., Shak S., Lieberman G., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 1999;17:2639–2648. doi: 10.1200/JCO.1999.17.9.2639.
- Yu G.Z., Chen Y., Wang J.J. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: Their relationship with clinicopathological parameters and prognostic significance. J. Cancer Res. Clin. Oncol. 2009;135:1331–1339. doi: 10.1007/s00432-009-0574-8.
- Scheel A.H., Penault-Llorca F., Hanna W., Baretton G., Middel P., Burchhardt J., Hofmann M., Jasani B., Rüschoff J. Physical basis of the ‘magnification rule’ for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer. Diagn. Pathol. 2018;13:19. doi: 10.1186/s13000-018-0696-x.
- Gowryshankar A., Nagaraja V., Eslick G.D. HER2 status in Barrett’s esophagus & esophageal cancer: A meta analysis. J. Gastrointest. Oncol. 2014;5:25–35. doi: 10.3978/j.issn.2078-6891.2013.039.
- Nagaraja V., Shaw N., Morey A.L., Cox M.R., Eslick G.D. HER2 expression in oesophageal carcinoma and Barrett’s oesophagus associated adenocarcinoma: An Australian study. Eur. J. Surg. Oncol. 2016;42:140–148. doi: 10.1016/j.ejso.2015.08.159.
- Parkin D.M., Bray F., Ferlay J., Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer. 2001;94:153–156. doi: 10.1002/ijc.1440.
- Chen K.H., Mukaisho K., Ling Z.Q., Shimomura A., Sugihara H., Hattori T. Association between duodenal contents reflux and squamous cell carcinoma—Establishment of an esophageal cancer cell line derived from the metastatic tumor in a rat reflux model. Anticancer Res. 2007;27:175–181.
- Nozoe T., Korenaga D., Kabashima A., Sugimachi K. Smoking-related increase of O(6)-methylguanine-DNA methyltransferase expression in squamous cell carcinoma of the esophagus. Cancer Lett. 2002;184:49–55. doi: 10.1016/S0304-3835(02)00188-X.
- Sami S.S., Iyer P.G. Recent Advances in Screening for Barrett’s Esophagus. Curr. Treat. Options Gastroenterol. 2018 doi: 10.1007/s11938-018-0166-2.
- Dulai G.S., Guha S., Kahn K.L., Gornbein J., Weinstein W.M. Preoperative prevalence of Barrett’s esophagus in esophageal adenocarcinoma: A systematic review. Gastroenterology. 2002;122:26–33. doi: 10.1053/gast.2002.30297.
- Runge T.M., Abrams J.A., Shaheen N.J. Epidemiology of Barrett’s Esophagus and Esophageal Adenocarcinoma. Gastroenterol. Clin. N. Am. 2015;44:203–231. doi: 10.1016/j.gtc.2015.02.001.
- Huo X., Juergens S., Zhang X., Rezaei D., Yu C., Strauch E.D., Wang J.Y., Cheng E., Meyer F., Wang D.H., et al. Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-κB activation in benign Barrett’s epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2011;301:G278–G286. doi: 10.1152/ajpgi.00092.2011.
- Miwa K., Sahara H., Segawa M., Kinami S., Sato T., Miyazaki I., Hattori T. Reflux of duodenal or gastro-duodenal contents induces esophageal carcinoma in rats. Int. J. Cancer. 1996;67:269–274. doi: 10.1002/(SICI)1097-0215(19960717)67:2<269::AID-IJC19>;2-6.
- Kumagai H., Mukaisho K., Sugihara H., Bamba M., Miyashita T., Miwa K., Hattori T. Cell kinetic study on histogenesis of Barrett’s esophagus using rat reflux model. Scand. J. Gastroenterol. 2003;38:687–692. doi: 10.1080/00365520310003435.
- Wang R.H. From reflux esophagitis to Barrett’s esophagus and esophageal adenocarcinoma. World J. Gastroenterol. 2015;21:5210–5219. doi: 10.3748/wjg.v21.i17.5210.
- Le May C., Chu K., Hu M., Ortega C.S., Simpson E.R., Korach K.S., Tsai M.J., Mauvais-Jarvis F. Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc. Natl. Acad. Sci. USA. 2006;103:9232–9237. doi: 10.1073/pnas.0602956103.
- Baker J., Liu J.P., Robertson E.J., Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell. 1993;75:73–82. doi: 10.1016/S0092-8674(05)80085-6.
- Gallagher E.J., LeRoith D. Minireview: IGF, Insulin, and Cancer. Endocrinology. 2011;152:2546–2551. doi: 10.1210/en.2011-0231.
- Clemmons D.R. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol. Metab. Clin. N. Am. 2012;41:425–443. doi: 10.1016/j.ecl.2012.04.017.
- Boucher J., Tseng Y.H., Kahn C.R. Insulin and insulin-like growth factor-1 receptors act as ligand-specific amplitude modulators of a common pathway regulating gene transcription. J. Biol. Chem. 2010;285:17235–17245. doi: 10.1074/jbc.M110.118620.
- Baserga R., Peruzzi F., Reiss K. The IGF-1 receptor in cancer biology. Int. J. Cancer. 2003;107:873–877. doi: 10.1002/ijc.11487.
- Guerard M., Robin T., Perron P., Hatat A.S., David-Boudet L., Vanwonterghem L., Busser B., Coll J.L., Lantuejoul S., Eymin B., et al. Nuclear translocation of IGF1R by intracellular amphiregulin contributes to the resistance of lung tumour cells to EGFR-TKI. Cancer Lett. 2018;420:146–155. doi: 10.1016/j.canlet.2018.01.080.
- Schnarr B., Strunz K., Ohsam J., Benner A., Wacker J., Mayer D. Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer. Int. J. Cancer. 2000;89:506–513. doi: 10.1002/1097-0215(20001120)89:6<506::AID-IJC7>;2-F.
- Kuklinski A., Kamocki Z., Koda M., Piotrowski Z., Sulkowski S., Lesniewicz R., Pawlak K., Mysliwiec P., Kedra B. IGF-IR in patients with advanced colorectal cancer in correlation with certain clinico-morphological factors: Initial report. Oncol. Lett. 2011;2:1155–1159. doi: 10.3892/ol.2011.396.
- Realdon S., Dassie E., Fassan M., Dall’Olmo L., Hatem G., Buda A., Arcidiacono D., Diamantis G., Zhang H., Greene M.I., et al. In vivo molecular imaging of HER2 expression in a rat model of Barrett’s esophagus adenocarcinoma. Dis. Esophagus. 2015;28:394–403. doi: 10.1111/dote.12210.
- Dassie E., Arcidiacono D., Wasiak I., Damiano N., Dall’Olmo L., Giacometti C., Facchin S., Cassaro M., Guido E., De Lazzari F., et al. Detection of fluorescent organic nanoparticles by confocal laser endomicroscopy in a rat model of Barrett’s esophageal adenocarcinoma. Int. J. Nanomed. 2015;10:6811–6823. doi: 10.2147/IJN.S86640.
Source: PubMed